Testosterone undecanoate (TU) - NebidoTM

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
74
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypogonadism

Conditions

Hypogonadism

Trial Timeline

Feb 1, 2003 โ†’ Oct 1, 2007

About Testosterone undecanoate (TU) - NebidoTM

Testosterone undecanoate (TU) - NebidoTM is a phase 3 stage product being developed by Bayer for Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT00220298. Target conditions include Hypogonadism.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00220298Phase 3Completed